| Document |
Document Title |
|
WO/2021/086077A1 |
The present invention relates to an isoquinolinone derivative, a preparation method therefor, and a pharmaceutical composition, comprising same as an active ingredient, for prevention or treatment of a poly(ADP-ribose)polymerase-1 (PARP-...
|
|
WO/2021/083182A1 |
A compound of a uricosuric agent used as a uric acid transporter (URAT1) inhibitor, and application thereof in preparation of a medication for treating a disease related to abnormal uric acid levels. The present invention specifically re...
|
|
WO/2021/085817A2 |
Provided is a tertiary amine derivative which effectively absorbs a high-energy external light source in the UV region, and thus minimizes damages to organic materials in an organic electroluminescent device, thereby contributing to a su...
|
|
WO/2021/087181A1 |
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and p...
|
|
WO/2021/087018A1 |
The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
|
|
WO/2021/086816A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described an...
|
|
WO/2021/086829A1 |
Provided herein are methods of using certain biomarkers, such as gene sets (e.g., a leukemic stem cell (LSC) signature), in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having v...
|
|
WO/2021/085370A1 |
The present invention addresses the problem of providing an excellent pesticide.　The prevent invention provides an azole derivative or an agrochemically acceptable salt thereof and a pesticide characterized by comprising the same as an...
|
|
WO/2021/080997A1 |
The present disclosure relates to 3-(4-(llH-dibenzo[b,e][l,4]azepin-6- yl)piperazin-l-yl)-, 3-(4-(dibenzo[b,f][l,4]oxazepin-ll-yl)piperazin-l- yl)-, 3-(4-(dibenzo[b,f][l,4]thiazepin-ll-yl)piperazin-l-yl)- and 3- (4-(dibenzo[b,f][l,4]diaz...
|
|
WO/2021/080013A1 |
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and metho...
|
|
WO/2021/081207A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2021/079380A1 |
The present invention relates to improved process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-
amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridi
n-3-yl)-5-oxopyrrolidine-2-carboxamide and...
|
|
WO/2021/078217A1 |
Disclosed are a 2,8-disubstituted tetracene derivative represented by formula (I), a preparation method therefor, and the use thereof. The compound can be used for preparing an organic semiconductor device, particularly an organic field-...
|
|
WO/2021/078301A1 |
Disclosed are compounds of formulae (I) and (II), or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, and the use thereof for treating diseases. R 1-A 1-LIN-A 2-R 2 (I) R 12-A 12-LIN-A 22-R 22 (II)
|
|
WO/2021/078174A1 |
Provided are a chiral sulfur oxide-containing aryl formamide compound and salt thereof, a preparation method therefor, a herbicidal composition, and an application. The structure of the compound is represented by formula I, wherein Z 1 a...
|
|
WO/2021/081528A1 |
Disclosed are 7-phenyl-2-aminoquinoline compounds that are shown to inhibit the biological activity of neuronal nitric oxide synthases (nNOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using...
|
|
WO/2021/078135A1 |
A pyrrole amide compound, a pharmaceutical composition thereof and use thereof. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.
|
|
WO/2021/073439A1 |
The present invention relates to a pyrazine derivative represented by formula (I) for preventing or treating a disease or condition related to abnormal SHP2 activity. Moreover, the present invention also provides a method for preparing s...
|
|
WO/2021/076886A1 |
The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or c...
|
|
WO/2021/077010A1 |
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Linda...
|
|
WO/2021/074281A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2021/074351A1 |
The present invention provides a compound of formula (I) and compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate. The ...
|
|
WO/2021/070150A1 |
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e
thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...
|
|
WO/2021/069721A1 |
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treat...
|
|
WO/2021/070090A1 |
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...
|
|
WO/2021/070957A1 |
Provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a medical composition which contains the same and is used to treat or prevent cognitive function diseases or disorders. [In the formula...
|
|
WO/2021/069575A1 |
The present invention relates to novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R1, R2, R3, R4, R5 and R6 have the meaning given in the description, to formulations and comp...
|
|
WO/2021/068179A1 |
The present invention provides novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R 1, R 2, R 3, R 4, R 5 and R 6 have the meaning given in the description, formulations and com...
|
|
WO/2021/070132A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...
|
|
WO/2021/069701A1 |
Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatme...
|
|
WO/2021/064677A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.
|
|
WO/2021/067696A1 |
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceu...
|
|
WO/2021/066573A1 |
The present invention pertains to: a novel compound; and a use thereof in treating autoimmune diseases. A pharmaceutical composition for treating or preventing autoimmune diseases containing the novel compound of the present invention ca...
|
|
WO/2021/063856A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/064142A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/067266A1 |
Disclosed herein are pyrrolidinyl-based compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
|
|
WO/2021/067827A1 |
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
|
|
WO/2021/063852A1 |
The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/067801A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...
|
|
WO/2021/067606A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
|
WO/2021/066922A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present i...
|
|
WO/2021/067654A1 |
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
|
|
WO/2021/057910A1 |
Disclosed is a peptidylarginine deiminase inhibitor and a use thereof. In particular, the present invention relates to a compound of peptidylarginine deiminase PAD4 inhibitor represented by formula (I) and various subformulas, a pharmace...
|
|
WO/2021/062003A1 |
The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysin...
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/057872A1 |
Disclosed are a compound represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuterated compound thereof, a composition which comprises the compound represented by general f...
|
|
WO/2021/061665A1 |
The present invention provides polycyclic thiazolidines, imidazolidines, oxazolidines, and related compounds, which are useful as integrin agonist prodrugs. Methods for the treatment of integrin-mediated diseases such as cancer are also ...
|
|
WO/2021/055612A1 |
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysos...
|
|
WO/2021/055744A1 |
Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ar, X1, X2, and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-...
|
